

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (canceled)
2. (previously presented) A catheter assembly comprising:
  - a catheter, the catheter comprising a catheter shaft, the catheter shaft defining a first guide wire lumen for passage of a first guide wire therethrough;
  - a rotatable sheath, the rotatable sheath extending around an exterior of at least a portion of the catheter shaft and rotatable relative to the catheter shaft at a position radially outward from the catheter shaft, the rotatable sheath having a length substantially less than that of the catheter shaft;
  - a secondary guide wire housing, the secondary guide wire housing defining a secondary guide wire lumen for passage of a secondary guide wire therethrough, at least a first distal portion of the guide wire housing in contact with at least a first proximal portion of the rotatable sheath; and
  - a stent, the stent being expandable from a reduced stent state to an expanded stent state, and defining a flow path between a proximal end opening and a distal end opening, the stent being at least partially constructed from a plurality of interconnected stent members that define a plurality of cell openings therebetween, each of the cell openings being in fluid communication with the flow path, in the reduced stent state the stent is positioned radially outward from and extends around an exterior of at least a portion of the rotatable sheath and at least a portion of the secondary guide wire housing, a distal end portion of the secondary guide wire housing exiting the flow path of the stent through one of the plurality of cell openings.
3. (original) The assembly of claim 2 wherein the stent is selected from at least one member of the group consisting of: a self-expanding stent, a balloon-expandable stent, a hybrid expandable stent and any combination thereof.

4-5. (canceled)

6. (original) The assembly of claim 2 wherein at least a portion of the stent is coated with at least one therapeutic agent.

7. (CURRENTLY AMENDED) The assembly of claim 6 wherein the at least one therapeutic agent is at least one non-genetic therapeutic agent selected from at least one member of the group consisting of: anti-thrombogenic agents ~~such as heparin, heparin derivatives, urokinase, and PPACK (dextrophenylalanine proline arginine chloromethylketone);~~ anti-proliferative agents ~~such as enoxaprin, angiopentin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid;~~ anti-inflammatory agents ~~such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine;~~ antineoplastic agents; ~~antineoplastic/antiproliferative/anti-miotoxic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors;~~ anesthetic agents ~~such as lidocaine, bupivacaine and ropivacaine;~~ anti-coagulants ~~such as D-Phe-Pro-Arg-chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;~~ vascular cell growth promoters; ~~promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters;~~ vascular cell growth inhibitors ~~such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin;~~ bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms.

8. (CURRENTLY AMENDED) The assembly of claim 6 wherein the at least one therapeutic agent is at least one genetic therapeutic agent selected from at least one member of

the group consisting of: anti-sense DNA and RNA; DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules; angiogenic factors including growth factors ~~such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor  $\alpha$  and  $\beta$ , platelet derived endothelial growth factor, platelet derived growth factor, tumor necrosis factor  $\alpha$ , hepatocyte growth factor and insulin like growth factor~~; cell cycle inhibitors including CD inhibitors, thymidine kinase ("TK") and other agents useful for interfering with cell proliferation; at least one of the family of bone morphogenic proteins ("BMP's") ~~such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7~~; dimeric proteins ~~such as homodimers, heterodimers, or combinations thereof, alone or together with other molecules~~; and molecules capable of inducing an upstream or downstream effect of a BMP ~~such as BMP~~, "hedgehog" proteins, or the DNA's encoding them ~~and any combinations thereof~~.

9. (CURRENTLY AMENDED) A catheter assembly comprising:

a catheter, the catheter comprising a catheter shaft, the catheter shaft defining a first guide wire lumen for passage of a first guide wire therethrough;

a rotatable sheath, the rotatable sheath being disposed about at least a portion of the catheter shaft and rotatable about and relative to the catheter shaft, the rotatable sheath having a length substantially less than that of the catheter shaft;

a secondary guide wire housing, the secondary guide wire housing defining a secondary guide wire lumen for passage of a secondary guide wire therethrough, at least a first distal portion of the guide wire housing being engaged to at least a first proximal portion of the rotatable sheath; and

a stent, the stent being expandable from a reduced stent state to an expanded stent state, and defining a flow path between a proximal end opening and a distal end opening, the stent being at least partially constructed from a plurality of interconnected stent members that define a plurality of cell openings therebetween, each of the cell openings being in fluid communication with the flow path, in the reduced stent state the stent is disposed about at least a portion of the rotatable sheath and at least a portion of the secondary guide wire housing, a distal end portion of

the secondary guide wire housing exiting the flow path of the stent through one of the plurality of cell openings,

at least a portion of the stent is coated with at least one therapeutic agent,

the at least one therapeutic agent is at least one type of cellular material selected from at least one member of the group consisting of: autologous cells of human origin (~~autologous or allogeneic~~); allogeneic cells of human origin; and xenogeneic cells of non-human origin (~~xenogeneic~~) and any combination thereof.

10. (CURRENTLY AMENDED) The assembly of ~~claim 6~~ claim 9 wherein the cellular material is selected from at least one member of the group consisting of: side population cells; lineage negative cells; lineage negative CD34<sup>-</sup> cells; lineage negative CD34<sup>+</sup> cells; lineage negative  $\gamma$ Kit<sup>+</sup> cells; mesenchymal stem cells; cord blood cells; ~~cardiac or other~~ tissue derived stem cells; whole bone marrow; bone marrow mononuclear cells; endothelial progenitor cells; satellite cells; muscle derived cells; go cells; endothelial cells; adult cardiomyocytes; fibroblasts; smooth muscle cells; cultures of mesenchymal stem cells with 5-aza forces differentiation into cardiomyocytes; adult cardiac fibroblasts + 5-aza; genetically modified cells; tissue engineered grafts; MyoD scar fibroblasts; Pacing cells; embryonic stem cell clones; embryonic stem cells; fetal or neonatal cells; immunologically masked cells; tissue engineered grafts; genetically modified cells; and teratoma derived cells ~~and any combinations thereof~~.

11. (CURRENTLY AMENDED) The assembly of claim 6 wherein the at least one therapeutic agent comprises at least one polymer coating, the at least one coating selected from at least one member of the group consisting of: polycarboxylic acids; cellulosic polymers, including cellulose acetate and cellulose nitrate; gelatin; polyvinylpyrrolidone; cross-linked polyvinylpyrrolidone; polyanhydrides including maleic anhydride polymers; polyamides; polyvinyl alcohols; copolymers of vinyl monomers ~~such as~~ including EVA; polyvinyl ethers; polyvinyl aromatics; polyethylene oxides; glycosaminoglycans; polysaccharides; polyesters including polyethylene terephthalate; polyacrylamides; polyethers; polyether sulfone; polycarbonate; polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene; halogenated polyalkylenes including polytetrafluoroethylene; polyurethanes;

polyorthoesters; proteins; polypeptides; silicones; siloxane polymers; polylactic acid; polyglycolic acid; polycaprolactone; polyhydroxybutyrate valerate and blends and copolymers thereof; coatings from polymer dispersions ~~such as polyurethane dispersions (BAYHDROL<sup>®</sup>), fibrin, collagen and derivatives thereof~~; polysaccharides ~~such as celluloses, starches, dextrans, alginates and derivatives~~; hyaluronic acid; squalene emulsions; polyacrylic acid, a copolymer of polylactic acid and polycaprolactone; medical-grade biodegradable materials ~~such as PGA-TMC, Tyrosine-Derived Polycarbonates and arylates~~; polycaprolactone co butyl acrylate and other copolymers; Poly-L-lactic acid blends with DL-Lactic Acid; Poly(lactic acid-co-glycolic acid); polycaprolactone co PLA; polycaprolactone co butyl acrylate and other copolymers; Tyrosine-Derived Polycarbonates and arylate; poly amino acid; polyphosphazenes; polyiminocarbonates; polydimethyltrimethylcarbonates; biodegradable CA/PO<sub>4</sub>'s; cyanoacrylate; 50/50 DLPLG; polydioxanone; polypropylene fumarate; polydepsipeptides; macromolecules ~~such as including~~ chitosan and Hydroxylpropylmethylcellulose; surface erodible material; maleic anhydride copolymers; zinc-calcium phosphate; amorphous polyanhydrides; sugar; carbohydrate; ~~gelatin~~; biodegradable polymers; and polymers dissolvable in bodily fluids; A block copolymers; and B block copolymers ~~and any combinations thereof~~.

12. (canceled)

13. (previously presented) A catheter assembly comprising:

a catheter, the catheter comprising a catheter shaft, the catheter shaft defining a first guide wire lumen for passage of a first guide wire therethrough;

a rotatable sheath, the rotatable sheath being disposed about at least a portion of the catheter shaft and rotatable about the catheter shaft, the rotatable sheath having a length substantially less than that of the catheter shaft and being rotatably disposed about at least a portion of a medical balloon;

a secondary guide wire housing, the secondary guide wire housing defining a secondary guide wire lumen for passage of a secondary guide wire therethrough, at least a first distal portion of the guide wire housing being engaged to at least a first proximal portion of the rotatable sheath;

the medical balloon fixedly mounted to the catheter shaft, the medical balloon expandable from a reduced configuration to an expanded configuration, the catheter shaft further defining an inflation lumen, the inflation lumen being in fluid communication with the medical balloon; and

a rotatable collar, the rotatable collar rotatably disposed about a portion of the catheter shaft proximal of the medical balloon, at least a first proximal portion of the secondary guide wire housing being engaged to at least a portion of the rotatable collar.

14. (original) The assembly of claim 13 wherein the rotatable collar defines a catheter shaft lumen therethrough, the catheter shaft being positioned within the catheter shaft lumen, the catheter shaft lumen having a diameter greater than an outer diameter of the catheter shaft.

15-35. (canceled).

36. (NEW) The assembly of claim 8 wherein the at least one therapeutic agent is a growth factor selected from at least one member of the group consisting of: acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor  $\alpha$  and  $\beta$ , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor  $\alpha$ , hepatocyte growth factor and insulin like growth factor.

37. (NEW) The assembly of claim 8 wherein the at least one therapeutic agent is a bone morphogenic proteins ("BMP's") selected from at least one member of the group consisting of: BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16.

38. (NEW) The assembly of claim 8 wherein the at least one therapeutic agent comprises a dimeric protein selected from at least one member of the group consisting of: homodimers and heterodimers.

39. (NEW) The assembly of claim 11 wherein the at least one therapeutic agent comprises at least one coating from polymer dispersion selected from at least one member of the group consisting of polyurethane dispersions, fibrin, collagen and derivatives thereof.

40. (NEW) The assembly of claim 11 wherein the at least one therapeutic agent comprises at least one polysaccharide selected from at least one member of the group consisting of: celluloses, starches, dextrans, alginates, and derivatives.

41. (NEW) The assembly of claim 11 wherein the at least one therapeutic agent comprises a medical-grade biodegradable material selected from at least one member of the group consisting of: PGA-TMC, Tyrosine-Derived Polycarbonates, and arylates.

42. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises a anti-thrombogenic agent selected from at least one member of the group consisting of: heparin, heparin derivatives, urokinase, and PPACK (dextrophenylalanine proline arginine chloromethylketone).

43. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises an anti-proliferative agent selected from at least one member of the group consisting of: enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid.

45. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises an anti-inflammatory agents selected from at least one member of the group consisting of: dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine.

46. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises an anti-coagulants selected from at least one member of the group consisting of: D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds,

platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides.

47. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises at least one member of the group consisting of: paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, and thymidine kinase inhibitors.

48. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises an anesthetic agent selected from at least one member of the group consisting of: lidocaine, bupivacaine, and ropivacaine.

49. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises a vascular cell growth promoters selected from at least one member of the group consisting of: growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters.

50. (NEW) The assembly of claim 7 wherein the at least one therapeutic agent comprises a vascular cell growth inhibitors selected from at least one member of the group consisting of: growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, and bifunctional molecules consisting of a growth factor and a cytotoxin.

51. (NEW) The assembly of claim 10 wherein the wherein the cellular material includes tissue derived stem cells including cardiac derived stem cells.